Real-time enrollment status for this hereditary transthyretin-mediated (hattr) amyloidosis clinical trial
Current Status
Recruiting
Checked: July 19, 2026 at 4:41 AM UTC
| NCT Number | NCT05040373 |
| Recruiting Status | Recruiting |
| Condition | Hereditary Transthyretin-mediated (hATTR) Amyloidosis |
| Phase | Clinical Trial |
| Target Enrollment | 10 participants |
| Active Locations | 1 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | June 1, 2026 (Jun 1, 2026) |
As of July 19, 2026: Clinical trial NCT05040373 is currently recruiting participants. This clinical trial study for hereditary transthyretin-mediated (hattr) amyloidosis is actively seeking new participants at 1 location across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05040373 is actively recruiting participants as of July 19, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05040373 was last updated Jun 1, 2026 (June 1, 2026). HelloStudys verifies this status automatically.